Llorente-Ramón A, Moreira-Alcívar JH, Barraza-Ortiz DA, Ramos-Aguilar GA, Mejía-Loza SAI

Language: Spanish
References: 30
Page: 188-195
PDF size: 247.03 Kb.

ABSTRACT

Primary biliary cholangitis is a chronic and progressive inflammatory autoimmune cholestatic liver disease characterized by the destruction of small intrahepatic bile ducts. It is considered a rare disease that predominates in women with a prevalence of 19 to 402 per million people. It is clinically characterized by fatigue, right upper quadrant pain, jaundice, pruritus, and biochemically with alkaline phosphatase (ALP) elevation at least › 1.5 times normal upper limit and the presence of mitochondrial antibody (AMA) positive at titers of 1:40 or more, liver biopsy is necessary in case of high suspicion and negative AMA or in case of suspected overlay syndrome (HAI/CBP). Early diagnosis and treatment of this disease can significantly improve the course of the disease by delaying liver cirrhosis and its complications and impacting patients’ quality of life.

REFERENCES

1. Beuers U, Gershwin ME, Gish RG et al. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis”. Hepatology 2015; 62: 1620-22.

2. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65: 321-9.

3. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144: 560-9.

4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-13.

5. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014; 34: 265-72.

6. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015; 386: 1565-75.

7. Borchers AT, Shimoda S, Bowlus C et al. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol 2009; 31: 309-22.

8. Yokomori H, Oda M, Ogi M et al. Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis. World J Gastroenterol 2005; 11: 4382-9.

9. Cordell HJ, Han Y, Mells GF, Li Y et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun 2015; 6: 8019.

10. Chang JC, Go S, de Waart DR et al. Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes. Hepatology 2016; 64: 522-34.

11. Myers RP, Shaheen AA, Fong A et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. Hepatology 2009; 50: 1884-92.

12. Lindor KD, Gershwin ME, Poupon R et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.

13. Goldblatt J, Taylor PJ, Lipman T et al. The true impact of fatigue in primary biliary 
cirrhosis: a population study. Gastroenterology 2002; 122: 1235-41.

14. Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol 
Res Pract 2015; 295891.

15. Raszeja-Wyszomirska J, Miazgowski T. Osteoporosis in primary biliary cirrhosis 
of the liver. Prz Gastroenterol 2014; 9: 82-7.

16. Liu B, Zhang FC, Zhang ZL et al. Interstitial lung disease and Sjogren’s syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 2008; 27: 1299-306.

17. Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56: 1409-17.

18. Hirschfield GM, Dyson JK, Alexander GJM et al. The British society of gastroenterology/UK-PBC primary biliary colangitis treatment and management guidelines. Gut 2018; 67: 1568-94.

19. Marzorati S, Invernizzi P, Lleo A. Making sense of autoantibodies in cholestatic liver diseases. Clin Liver Dis 2016; 20: 33-46.

20. Nakamura M. Clinical significance of autoantibodies in primary biliary cirrhosis. Semin Liver Dis 2014; 34: 334-40.

21. Mells GF, Hirschfield GM. Making the most of new genetic risk factors: genetic and epigenetic fine mapping of causal autoimmune disease variants. Clin Res Hepatol Gastroenterol 2015; 39: 408-11.

22. Khan FM, Komarla AR, Mendoza PG et al. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: “minimal change PBC”. Hepatology 2013; 57: 700-7.

23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145-72.

24. Hirschfield GM, Mason A, Luketic V et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-61.

25. Nakanuma YZY, Portmann B. MacSween’s pathology of the liver. Philadelphia: Elsevier, 2012.

26. Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-49.

27. Carbone M, Sharp SJ, Flack S et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016; 63: 930-50.

28. Beuers U, Trauner M, Jansen P et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: S25-37.

29. Beyers U, Kremer AE, Bolier R et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60: 399-407.

30. Martin P, DiMartini A, Feng S et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144-65.